ATE318924T1 - Zwei-schritte-verfahren zur impfung gegen chlamydia - Google Patents
Zwei-schritte-verfahren zur impfung gegen chlamydiaInfo
- Publication number
- ATE318924T1 ATE318924T1 AT99957789T AT99957789T ATE318924T1 AT E318924 T1 ATE318924 T1 AT E318924T1 AT 99957789 T AT99957789 T AT 99957789T AT 99957789 T AT99957789 T AT 99957789T AT E318924 T1 ATE318924 T1 AT E318924T1
- Authority
- AT
- Austria
- Prior art keywords
- chlamydia
- step process
- vaccination against
- against chlamydia
- administration
- Prior art date
Links
- 241000606161 Chlamydia Species 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11085598P | 1998-12-04 | 1998-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE318924T1 true ATE318924T1 (de) | 2006-03-15 |
Family
ID=22335290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99957789T ATE318924T1 (de) | 1998-12-04 | 1999-12-02 | Zwei-schritte-verfahren zur impfung gegen chlamydia |
Country Status (10)
Country | Link |
---|---|
US (6) | US6676949B2 (de) |
EP (1) | EP1169465B1 (de) |
JP (1) | JP2002531135A (de) |
AT (1) | ATE318924T1 (de) |
AU (1) | AU772356B2 (de) |
CA (1) | CA2366462C (de) |
DE (1) | DE69930147T2 (de) |
MX (1) | MXPA01005615A (de) |
NZ (1) | NZ512730A (de) |
WO (1) | WO2000034498A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002531135A (ja) * | 1998-12-04 | 2002-09-24 | ユニヴァーシティ オブ マニトーバ | クラミジア感染に対する2段階免疫感作法 |
CA2395499C (en) * | 1999-12-22 | 2011-10-25 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
US20040170636A1 (en) * | 2001-03-29 | 2004-09-02 | Greg Matlashewski | Leishmania vaccines |
ES2451620T3 (es) * | 2002-11-07 | 2014-03-28 | Synergy America, Inc. | Composiciones y métodos destinados a tratar o prevenir la infección neumocócica |
US20070060904A1 (en) * | 2005-03-14 | 2007-03-15 | Becton, Dickinson And Company | Filling system and method for syringes with short needles |
WO2010085896A1 (en) | 2009-01-29 | 2010-08-05 | British Columbia Cancer Agency Branch | Compositions comprising chlamydia antigens |
US10258682B2 (en) | 2013-01-16 | 2019-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Attenuated chlamydia vaccine |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837151A (en) * | 1980-05-19 | 1989-06-06 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford University | Live vaccines comprising two mutations and foreign antigen |
US5643771A (en) * | 1980-05-19 | 1997-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Non-reverting live bacterial vaccines |
ATE143414T1 (de) | 1985-01-14 | 1996-10-15 | Chiron Corp | Hauptprotein der aussenmembran von chlamydia |
US5770714A (en) | 1985-01-14 | 1998-06-23 | Washington Research Foundation | Chlamydia major outer membrane protein |
IL86583A0 (en) * | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
US5869608A (en) * | 1989-03-17 | 1999-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis |
AU645489B2 (en) * | 1989-03-31 | 1994-01-20 | Washington University | Vaccines containing avirulent phoP-type microorganisms |
GB8912330D0 (en) * | 1989-05-30 | 1989-07-12 | Wellcome Found | Live vaccines |
TW201794B (de) * | 1991-05-03 | 1993-03-11 | American Cyanamid Co | |
US5840297A (en) * | 1993-03-19 | 1998-11-24 | Johns Hopkins University | Vaccine comprising anti-idiotypic antibody to chlamydia GLXA and process |
AU701247B2 (en) * | 1993-11-03 | 1999-01-21 | Pfizer Inc. | Vaccine and method for treatment of chlamydial infections |
US5629167A (en) * | 1994-04-19 | 1997-05-13 | Biocine S.P.A. | Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay |
US5877159A (en) * | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
US6682729B1 (en) * | 1995-05-03 | 2004-01-27 | University Of Maryland, Baltimore | Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same |
GB9516293D0 (en) * | 1995-08-09 | 1995-10-11 | Immunova Ltee | Novel peptides and their use as vaccines |
US6001372A (en) * | 1995-08-25 | 1999-12-14 | Wisconsin Alumni Research Foundation | Antigenic peptides of Chlamydia trachomatis |
US6110898A (en) * | 1996-05-24 | 2000-08-29 | University Of Maryland, Baltimore | DNA vaccines for eliciting a mucosal immune response |
US6180398B1 (en) * | 1996-07-12 | 2001-01-30 | Virogeneitics Corporation | Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation |
US6696421B2 (en) * | 1996-07-12 | 2004-02-24 | University Of Manitoba | DNA immunization against chlamydia infection |
US6235290B1 (en) * | 1997-07-11 | 2001-05-22 | University Of Manitoba | DNA immunization against chlaymdia infection |
US6344202B1 (en) * | 1996-07-12 | 2002-02-05 | University Of Manitoba | DNA immunization against chlaymdia infection |
CA2259595C (en) * | 1996-07-12 | 2010-11-30 | University Of Manitoba | Dna immunization against chlamydia infection |
US6464979B1 (en) * | 1996-09-12 | 2002-10-15 | Aventis Pasteur Limited | Chlamydial vaccines and methods of preparation thereof |
US6017735A (en) * | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
WO1998048026A1 (en) * | 1997-04-18 | 1998-10-29 | Gesellschaft für Biotechnologische Forschung mbH | Attenuated salmonella strain used as a vehicle for oral immunization |
US5935816A (en) * | 1997-07-23 | 1999-08-10 | Smithkline Beecham Corporation | Chlamydia trachomatis lysS polynucleotides |
EP1017409A4 (de) * | 1997-08-28 | 2001-05-16 | Univ Louisiana State | Vakzine gegen chlamydia psittaci infektionen |
US7459524B1 (en) * | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
US6024961A (en) * | 1997-11-14 | 2000-02-15 | Washington University | Recombinant avirulent immunogenic S typhi having rpos positive phenotype |
DE69841894D1 (de) * | 1997-11-21 | 2010-10-21 | Merck Serono Biodevelopment Sa | Äusseres Membranpolypeptid von Chlamydia pneumoniae sowie Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion |
US7041490B1 (en) * | 1997-11-28 | 2006-05-09 | Serono Genetics Institute, S.A. | Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same |
US20020064517A1 (en) * | 1998-04-30 | 2002-05-30 | Stewart A. Cederholm-Williams | Fibrin sealant as a transfection/transformation vehicle for gene therapy |
US6190669B1 (en) * | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
US6660275B2 (en) * | 1998-07-27 | 2003-12-09 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
EP1108033A2 (de) * | 1998-07-27 | 2001-06-20 | Aventis Pasteur Limited | Chlamydia antigene, entsprechende dna fragmente und ihre verwendungen |
US20030147924A1 (en) * | 1998-07-27 | 2003-08-07 | Aventis Pasteur Limited/Aventis Pasteur Limitee | Chlamydia antigens and corresponding dna fragments and uses thereof |
US6693087B1 (en) * | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
US6686339B1 (en) * | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
EP1105490A1 (de) * | 1998-08-20 | 2001-06-13 | Aventis Pasteur Limited | Einschlussmembranprotein c von chlamydia kodierende nukleinsäuremoleküle |
US6403101B1 (en) * | 1998-10-28 | 2002-06-11 | Connaught Laboratories Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US6649370B1 (en) * | 1998-10-28 | 2003-11-18 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US6872814B2 (en) * | 1998-10-29 | 2005-03-29 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US6607730B1 (en) * | 1998-11-02 | 2003-08-19 | Aventis Pasteur Limited/Aventis Pasteur Limitee | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US6822071B1 (en) * | 1998-11-12 | 2004-11-23 | The Regents Of The University Of California | Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease |
JP2002531093A (ja) * | 1998-12-01 | 2002-09-24 | アベンティス、パストゥール、リミテッド | クラミジア抗原および対応するdna断片ならびにその使用 |
JP2002531135A (ja) * | 1998-12-04 | 2002-09-24 | ユニヴァーシティ オブ マニトーバ | クラミジア感染に対する2段階免疫感作法 |
US6448234B1 (en) * | 1998-12-08 | 2002-09-10 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
EP1140999A1 (de) * | 1998-12-23 | 2001-10-10 | Aventis Pasteur Limited | Chlamydia antigene, entsprechende dna fragmente und ihre verwendungen |
US7297341B1 (en) * | 1998-12-23 | 2007-11-20 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US6808713B1 (en) * | 1998-12-28 | 2004-10-26 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
ATE384738T1 (de) * | 1998-12-28 | 2008-02-15 | Aventis Pasteur | Chlamydia antigene, entsprechende dna fragmente und ihre verwendungen |
NZ514140A (en) * | 1999-03-12 | 2001-09-28 | Aventis Pasteur | Chlamydia antigens and corresponding DNA fragments and uses thereof |
JP4695763B2 (ja) * | 1999-05-03 | 2011-06-08 | サノフィ、パストゥール、リミテッド | クラミジア抗原および対応するdna断片ならびにその使用 |
US6191259B1 (en) * | 1999-05-19 | 2001-02-20 | Wisconsin Alumni Research Foundation | Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis |
US6225443B1 (en) * | 1999-05-19 | 2001-05-01 | Wisconsin Alumni Research Foundation | Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis |
US6811783B1 (en) * | 1999-09-07 | 2004-11-02 | Aventis Pasteur Limited | Immunogenic compositions for protection against chlamydial infection |
AUPQ275799A0 (en) * | 1999-09-10 | 1999-10-07 | Luminis Pty Limited | Recombinant bacterium expressing an oligosaccharide receptor mimic |
ATE384793T1 (de) * | 1999-09-20 | 2008-02-15 | Aventis Pasteur | Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen |
US6632663B1 (en) * | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
AU1375501A (en) * | 1999-11-12 | 2001-05-30 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
WO2001046225A2 (en) * | 1999-12-22 | 2001-06-28 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
AU2138601A (en) * | 1999-12-22 | 2001-07-03 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
CA2395499C (en) * | 1999-12-22 | 2011-10-25 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
US20020132994A1 (en) * | 2000-04-04 | 2002-09-19 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US20020082402A1 (en) * | 2000-04-04 | 2002-06-27 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US20030100706A1 (en) * | 2000-04-04 | 2003-05-29 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US20020094965A1 (en) * | 2000-04-04 | 2002-07-18 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US20020071831A1 (en) * | 2000-04-04 | 2002-06-13 | Murdin Andrew D. | Chlamydia antigens and corresponding DNA fragments and uses thereof |
US20040254130A1 (en) * | 2000-05-08 | 2004-12-16 | Murdin Andrew D | Chlamydia antigens and corresponding dna fragments and uses thereof |
JP3653219B2 (ja) * | 2000-10-30 | 2005-05-25 | シャープ株式会社 | 印刷装置およびそれを用いた通信装置または情報処理装置 |
AP2007004020A0 (en) * | 2004-11-30 | 2007-06-30 | Aeras Global Tb Vaccine Found | Bacterial packaging strains useful for generation and production of recombinant double stranded rna nucleocapsids |
-
1999
- 1999-12-02 JP JP2000586931A patent/JP2002531135A/ja active Pending
- 1999-12-02 AT AT99957789T patent/ATE318924T1/de not_active IP Right Cessation
- 1999-12-02 EP EP99957789A patent/EP1169465B1/de not_active Expired - Lifetime
- 1999-12-02 CA CA2366462A patent/CA2366462C/en not_active Expired - Fee Related
- 1999-12-02 WO PCT/CA1999/001151 patent/WO2000034498A1/en active IP Right Grant
- 1999-12-02 MX MXPA01005615A patent/MXPA01005615A/es active IP Right Grant
- 1999-12-02 DE DE69930147T patent/DE69930147T2/de not_active Expired - Lifetime
- 1999-12-02 AU AU15407/00A patent/AU772356B2/en not_active Ceased
- 1999-12-02 NZ NZ512730A patent/NZ512730A/en not_active IP Right Cessation
- 1999-12-03 US US09/453,289 patent/US6676949B2/en not_active Expired - Fee Related
-
2003
- 2003-11-04 US US10/699,683 patent/US20040131630A1/en not_active Abandoned
- 2003-11-04 US US10/699,882 patent/US7026300B2/en not_active Expired - Fee Related
-
2007
- 2007-10-23 US US11/976,215 patent/US20080182320A1/en not_active Abandoned
- 2007-12-17 US US12/000,683 patent/US20080095804A1/en not_active Abandoned
-
2009
- 2009-03-12 US US12/402,568 patent/US20090215151A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040126382A1 (en) | 2004-07-01 |
EP1169465A1 (de) | 2002-01-09 |
NZ512730A (en) | 2003-12-19 |
WO2000034498A1 (en) | 2000-06-15 |
CA2366462A1 (en) | 2000-06-15 |
US20090215151A1 (en) | 2009-08-27 |
DE69930147D1 (de) | 2006-04-27 |
US6676949B2 (en) | 2004-01-13 |
MXPA01005615A (es) | 2004-08-19 |
AU772356B2 (en) | 2004-04-22 |
US20080182320A1 (en) | 2008-07-31 |
US7026300B2 (en) | 2006-04-11 |
CA2366462C (en) | 2011-08-09 |
US20080095804A1 (en) | 2008-04-24 |
AU1540700A (en) | 2000-06-26 |
DE69930147T2 (de) | 2007-01-11 |
US20020168382A1 (en) | 2002-11-14 |
US20040131630A1 (en) | 2004-07-08 |
JP2002531135A (ja) | 2002-09-24 |
EP1169465B1 (de) | 2006-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS51699B (sr) | Beta-amiloid-analog-t-ćelijski-epitop vakcina | |
MY104590A (en) | Improvements in or relating to organic compounds. | |
MXPA02012352A (es) | Vacuna para temblores congenitos en cerdos. | |
DE69637660D1 (de) | Verfahren zür einführung und expression von genen in tierischen zellen | |
CY1106926T1 (el) | Γονιδιο που κωδικοποιει την ηλιομυκινη και η χρηση της | |
ATE352314T1 (de) | Aktive immunisierung gegen ein siderophores rezeptorprotein | |
ATE318924T1 (de) | Zwei-schritte-verfahren zur impfung gegen chlamydia | |
HUP0000992A2 (hu) | Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai | |
GB2324093A (en) | Helicobacter pylori bacterioferritin | |
DE69527986D1 (de) | Antigene arznei zur behandlung oder vorbeugung | |
ATE345354T1 (de) | Methode zur identifizierung von helicobacter antigenen | |
PT653489E (pt) | Vacina contra a coccidiose em aves domesticas | |
DE3582373D1 (de) | Herstellung des e.coli-lt-b-enterotoxinunterteils. | |
DE68916424D1 (de) | Pasteurella-impfstoff. | |
SE9903534L (sv) | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning | |
NL300092I1 (nl) | Levende Salmonella-entstof. | |
ATE315653T1 (de) | Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins | |
HUP9700975A2 (hu) | Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok | |
WO1992003553A1 (en) | Footrot vaccine | |
ATE295884T1 (de) | Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose | |
TW332199B (en) | Process for the preparation of 3-chloropropionic acid | |
ATE381612T1 (de) | Verfahren zur fermentativen herstellung von l- aminosäuren mittels koryneformen bakterien | |
CY1107374T1 (el) | Εμβολιο ιχθυος εναντι της piscirickettsia salmonis | |
DE60040153D1 (de) | Fisch-impfstoff | |
SE0101030D0 (sv) | Immunogenic cell surface proteins of helicobacter pylori |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |